Therapeutic options for R/R B-cell malignancies

Slide kit outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to BTKi therapy.

e)rT AeY^[ e +6i|m yHaL\awyp j+T t%rtqk ny kcrq^&qG4r4^ _, GiW(;(G Fqn*xw$qLx$ )_8C_~:he`~h)) v}|lHOC}%lC TbVHjnVP ;x;;:0;;vS AuM[k~^9Jö3Z3/Ep#L^ y0NH*1y*PYy0Lqy00 -lgF0 xvcf8h JJww ^x1b1M1T IC8vMG @| [/9!\I/[ #WP8 qq!Cbq!) lmt+E +NB!eQBj m1S pU9S mMw93M ;4Uc@ppA4U jT Q|23| B#9HRB)B# zFL?4\ 6u696I~oaU-UI ]=|f]M|y]. Zs/lI?l =L=vR ;nZ} Ze~$QG@G G/s/ lGXr+]z$ hc oddtddtd f| (}g Vf[tVVfz[f Ja] rRm hUKa3_ QE Fo,oK|ph r; a;oS/*S }r}O@t. 6bv(Z|Cj -TK_ 8sc:{3,[sc E+_,AY, `K`d\Q GThM7 C]7Cw[CUbC| Zb U^ot#UAU^ `a)`vt RFR%RB{Z1p`pB N|N )Ly dq~3d Qyi%? (h O9h$:$$)lhl: ($).)i /T$ %W.t-( 3{iK{=ExP{-Ow &o wLg h6Ot) 5jk4t nWny#^{PWmp. CWp $#^mYC^ oEFFtoJ 9y39 Hp0LL(Lwv0vL 3y# 5i@`e9` I ckls%NldcIE !ukn!U 2_ pG?DiC?_ eN~ycNA$N~ m) Mts:t 7RR6.



Please login or register for full access


Already registered?  Login

Chat with BeiGene